Mitsubishi UFJ Trust & Banking’s Acadia Pharmaceuticals ACAD Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$496K	Buy	+19,618	New	+$432K	﹤0.01%	1056

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's ACAD Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 19,618 shares worth $496K. The stake represents ﹤0.01% of the portfolio and ranks #1056 among its holdings.

352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 19,618 shares of Acadia Pharmaceuticals worth $496K as of Q2 2026.
Acadia Pharmaceuticals was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1056 holding.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.